# Avid Radiopharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avid-radiopharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Philadelphia, US
- Website: www.avidrp.com
- Total disclosed funding: $70M
- Latest round: Series D (May 21, 2009)
- Investors on record: 8

## About

Avid Radiopharmaceuticals develops diagnostic solutions that enhance early disease diagnosis and treatment monitoring, focusing on neurodegenerative diseases such as Alzheimer’s, through advanced imaging technologies.Avid Radiopharmaceuticals is dedicated to developing innovative PET imaging agents for neurodegenerative disease diagnostics. The company was acquired in November 2010 by Eli Lilly for USD 800 mn. Its headquarters is located in Philadelphia, US, and the company has conducted five deals to date, with its most recent deal occurring on November 8, 2010. The company was founded by a team of individuals committed to advancing medical diagnostics.Avid Radiopharmaceuticals specializes in the development of advanced diagnostic solutions aimed at improving patient outcomes through early disease diagnosis and monitoring treatment effects. The company’s core product offerings include Amyvid, launched in 2012, and Tauvid, introduced in 2020, both FDA-approved PET imaging agents designed to identify amyloid plaques and tau proteins associated with neurodegenerative diseases. Avid serves a diverse clientele, including healthcare providers, hospitals, and research institutions across North America and Europe, enhancing clinical decision-making and patient care through its diagnostic technology.Avid Radiopharmaceuticals generates revenue through the sales of its diagnostic imaging agents, Amyvid and Tauvid, to healthcare institutions and providers. Transactions are conducted through direct sales to hospitals and clinics, integrating these diagnostic tools into routine clinical practice. The revenue model is structured around facilitating accurate diagnoses for patients with suspected neurodegenerative conditions, strengthening partnerships with healthcare professionals to drive product adoption.Following its acquisition by Eli Lilly in 2010, Avid Radiopharmaceuticals plans to leverage its resources for the development of new diagnostic products aimed at further enhancing its portfolio in neurodegenerative disease diagnostics. The company is also looking to expand into new markets, including additional healthcare providers in Europe and North America. The funding from its latest acquisition is expected to support these growth initiatives as they continue to advance their imaging technologies.

## Funding rounds

- Series D, May 21, 2009, $35M — Alta Partners, Safeguard Scientifics, Lilly Ventures, OUP (Osage University Partners), Pfizer Venture Investments, BioAdvance, RK Ventures Group, AllianceBernstein
- Series C, May 16, 2007, $26M — Safeguard Scientifics, Lilly Ventures, Pfizer Venture Investments, BioAdvance, RK Ventures Group, AllianceBernstein
- Series A, Jan 5, 2006, $8.9M — Lilly Ventures, Pfizer Venture Investments, BioAdvance, RK Ventures Group
- Seed, Jan 25, 2005, $0.5M — BioAdvance

## Investors

- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Seed, Series A, Series C, Series D
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A, Series C, Series D
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A, Series C, Series D
- RK Ventures Group — Series A, Series C, Series D
- Safeguard Scientifics (https://capitalatlas.ai/funds/safeguard-scientifics) — Series C, Series D
- AllianceBernstein (https://capitalatlas.ai/funds/alliancebernstein) — Series C, Series D
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series D
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series D